NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel cancer therapeutics, today announced that data published in the Journal of Clinical Oncology suggest that patients with unresectable metastatic colorectal cancer (mCRC) refractory to systemic chemotherapy can achieve substantial regression of their liver metastases with ERBITUX® (cetuximab), thereby increasing the potential for these patients to become candidates for complete surgical resection of their metastatic disease.1
